Inventiva Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Inventiva (EPA:IVA) Full Year 2024 Results

Key Financial Results

• Revenue: €14.1m (down 38% from FY 2023).
• Net loss: €184.2m (loss widened by 67% from FY 2023).
• €3.08 loss per share (further deteriorated from €2.44 loss in FY 2023).

Our free stock report includes 4 warning signs investors should be aware of before investing in Inventiva. Read for free now.

IVA Products In Clinical Trials

• Phase II: 1.
• Phase III: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Inventiva Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) missed analyst estimates by 153%.

In the last 12 months, the only revenue segment was Pharmaceuticals contributing €14.7m. The most substantial expense, totaling €88.3m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how IVA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's shares are up 3.6% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Inventiva (at least 2 which are significant), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.